Prof. Peter Mol, Netherlands

Peter Mol is the Committee for Medicinal Products for Human Use (CHMP) member for the Dutch Medicines Evaluation Board. He was from 2012 to 2023 member (vice chair 2016-2022) of EMA's Scientific Advice Working Party. He has coordinated over 300 EMA and national scientific advice procedures for drug development programs for cardiometabolic, gynecology and hematology products. He was chair of the EMA Cross-Committee Task force on Registries (2016-2023).

He is also a professor of drug regulatory science at the University Medical Center Groningen. His research focuses on developing new tools to support regulatory decision-making and the exchange of knowledge between regulatory authorities, health care professionals and lay people. He is currently involved in projects around personalized medicine, new data sources (RWE), patient-centric ways to weigh drug benefit-risk, e.g., using Patient Relevant Outcomes, Quality of Life, and Patient Preference information, and on risk communication, e.g., Direct Healthcare Provider Communication. He is Principal Investigator of the HORIZON More-EUROPA project.